Corbus Pharmaceuticals Holdings (CRBP) Liabilities and Shareholders Equity (2013 - 2025)

Corbus Pharmaceuticals Holdings' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $168.2 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 7.9% year-over-year to $168.2 million; the TTM figure through Dec 2025 stood at $542.7 million (down 9.21% YoY), while the FY2025 annual figure was $168.2 million, up 7.9% from the prior year.
• Liabilities and Shareholders Equity was $168.2 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $109.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $168.2 million in Q4 2025 to a low of $28.3 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $105.3 million across 5 years, with a median of $114.5 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity slumped 57.37% in 2023, then soared 451.35% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $107.7 million in 2021, then slumped by 38.45% to $66.3 million in 2022, then plunged by 57.37% to $28.3 million in 2023, then jumped by 451.35% to $155.9 million in 2024, then increased by 7.9% to $168.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $168.2 million (Q4 2025), $109.5 million (Q3 2025), and $125.1 million (Q2 2025), per Business Quant data.